Security Snapshot

Adverum Biotechnologies, Inc. - Common Stock, par value $0.0001 per share (ADVM) Institutional Ownership

CUSIP: 00773U108

13F Institutional Holders and Ownership History from Q1 2016 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

0

Shares (Excl. Options)

0

Price

Save this security research path

Keep this CUSIP in your research flow, then return after the next filing cycle to check what changed.

Create free account to save this research Review latest holder period
Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
ADVM on Nasdaq
Shares outstanding
22,163,711
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
0
Total reported value
$0
Share change
-506,821
Value change
-$2,295,899
Number of holders
0
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • ADVM - Adverum Biotechnologies, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 00773U108.
  • 0 institutions reported positions in Q4 2025.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
  • Reported value moved from $2,295,899 to $0.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Official SEC Source

Backed by Form 13F

Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.

See Original Filing

Investment Quick Answers

What is CUSIP 00773U108?
CUSIP 00773U108 identifies ADVM - Adverum Biotechnologies, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Adverum Biotechnologies, Inc. - Common Stock, par value $0.0001 per share (ADVM) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TCG Crossover GP II, LLC 8.9% 1,871,482 TCG Crossover GP II, LLC 31 Mar 2025

As of 31 Dec 2025, 0 institutional investors reported holding 0 shares of Adverum Biotechnologies, Inc. - Common Stock, par value $0.0001 per share (ADVM). This represents 0% of the company’s total 22,163,711 outstanding shares.

Institutional Holders of Adverum Biotechnologies, Inc. - Common Stock, par value $0.0001 per share (ADVM) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$2,295,899 0
2025 Q3 506,821 $2,295,899 $4.53 1
2025 Q2 506,821 $1,089,665 $2.15 1
2025 Q1 506,821 $2,214,808 $4.37 1
2024 Q4 506,821 $2,366,854 $4.67 1
2024 Q3 506,821 $3,557,883 -$13,777,212 $7.02 1
2024 Q2 2,515,161 $17,254,004 -$15,119,117 $6.86 2
2024 Q1 3,584,406 $50,683,501 -$65,439,463 $14.14 3
2023 Q4 64,132,473 $48,273,518 -$1,520,387 $0.75 59
2023 Q3 65,292,701 $97,938,144 -$602,707 $1.50 59
2023 Q2 65,656,058 $104,390,959 +$5,754,060 $1.59 58
2023 Q1 62,720,205 $44,991,824 +$4,081,826 $0.72 55
2022 Q4 57,295,790 $33,199,851 -$12,964,215 $0.58 57
2022 Q3 58,514,356 $55,588,188 -$1,275,581 $0.95 71
2022 Q2 57,970,602 $69,560,336 -$6,820,507 $1.20 68
2022 Q1 62,888,494 $82,380,013 -$1,371,697 $1.31 83
2021 Q4 65,600,223 $115,457,496 -$8,004,076 $1.76 93
2021 Q3 69,635,091 $151,153,216 -$23,142,215 $2.17 106
2021 Q2 78,711,144 $275,485,634 -$213,058,010 $3.50 112
2021 Q1 95,104,058 $937,859,079 +$7,873,874 $9.86 131
2020 Q4 94,361,848 $1,022,948,988 -$6,881,994 $10.84 152
2020 Q3 95,172,816 $980,341,669 +$112,519,116 $10.30 158
2020 Q2 80,871,445 $1,688,585,259 +$34,736,142 $20.88 140
2020 Q1 80,026,922 $782,228,273 +$235,883,947 $9.77 125
2019 Q4 56,103,335 $646,305,236 +$34,182,922 $11.52 114
2019 Q3 48,990,703 $267,003,291 -$13,477,648 $5.45 98
2019 Q2 46,363,555 $548,900,478 +$95,034,106 $11.89 93
2019 Q1 39,718,110 $208,116,336 +$8,512,594 $5.24 83
2018 Q4 38,437,133 $121,095,668 -$70,697,347 $3.15 83
2018 Q3 34,548,140 $269,455,188 -$3,691,162 $6.05 101
2018 Q2 36,661,531 $194,311,714 +$10,169,062 $5.30 99
2018 Q1 34,592,324 $200,632,035 +$91,767,314 $5.80 95
2017 Q4 19,222,404 $67,283,021 +$19,583,575 $3.50 63
2017 Q3 13,572,084 $49,476,022 +$3,295,007 $3.65 56
2017 Q2 13,013,740 $32,536,015 -$1,444,466 $2.50 60
2017 Q1 13,521,554 $36,511,138 +$2,251,986 $2.70 72
2016 Q4 15,096,238 $43,780,064 -$552,911 $2.90 80
2016 Q3 15,269,145 $62,723,851 -$931,562 $4.11 75
2016 Q2 15,771,305 $49,835,686 +$49,081,893 $3.16 75
2016 Q1 226,341 $1,170,000 +$1,139,000 $5.17 3

Sponsored